Brought to you by 
Bayer and GlaxoSmithKline co-promote ED drug
23 Jul 2002
Executive Summary
Bayer and GlaxoSmithKline will develop Bayer's vardenafil and co-promote it globally, except in Japan. The oral product is a phosphodiesterase-5 inhibitor for erectile dysfunction.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer and GlaxoSmithKline co-promote ED drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice